keyword
MENU ▼
Read by QxMD icon Read
search

leptomeningeal carcinomatosis nsclc

keyword
https://www.readbyqxmd.com/read/28225456/efficacy-of-bevacizumab-and-erlotinib-combination-for-leptomeningeal-carcinomatosis-after-failure-of-erlotinib
#1
Ryo Ariyasu, Atsushi Horiike, Junji Koyama, Masafumi Saiki, Tomoaki Sonoda, Yosuke Kawashima, Natsuki Takano, Tomoyo Oguri, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Fumiyoshi Ohyanagi, Makoto Nishio
In patients with non-small-cell lung cancer harboring an epithelial growth factor receptor (EGFR) active mutation, central nervous system progression after a response to EGFR tyrosine kinase inhibitors is frequent. Central nervous system metastasis, especially leptomeningeal carcinomatosis (LMC), is a serious complication and no standard treatment has been established for LMC. Here, we report two cases in which the addition of bevacizumab to erlotinib enhanced the efficacy against LMC; as a result, radiographic abnormalities decreased markedly and symptoms were well controlled...
February 20, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28149755/state-of-the-art-of-chemotherapy-for-the-treatment-of-central-nervous-system-metastases-from-non-small-cell-lung-cancer
#2
REVIEW
Alessandro Inno, Vincenzo Di Noia, Ettore D'Argento, Alessandra Modena, Stefania Gori
Chemotherapy is the mainstay of treatment of advanced non-small cell lung cancer (NSCLC) without molecular drivers. Despite a low penetration of central nervous system (CNS), chemotherapy drugs demonstrated encouraging activity against CNS metastases from NSCLC. Based on the available data, chemotherapy should be considered as an important part of the multidisciplinary treatment of CNS metastases. Particularly, platinum-based regimens represent the most active combinations and pemetrexed is associated with a meaningful clinical benefit for patients with non-squamous histology...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28110254/leptomeningeal-carcinomatosis-in-non-small-cell-lung-cancer-patients-a-continuing-challenge-in-the-personalized-treatment-era
#3
REVIEW
J Remon, E Le Rhun, B Besse
Leptomeningeal metastasis is a fatal manifestation seen in advanced cancer patients. Its incidence is increasing, reaching 3.8% in molecularly unselected non-small cell lung cancer patients and up to 5% and 9% in ALK-rearranged and EGFR-mutant lung cancer patients, respectively. The prognosis remains poor despite systemic treatment, intrathecal chemotherapy, radiation therapy and personalized treatments in molecularly selected patients. However, new therapies with improved cerebral-spinal fluid penetration have been developed for subgroups of molecular selected patients indicating they could be promising therapeutic options for managing leptomeningeal disease...
February 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28064206/retrospective-analysis-of-survival-in-patients-with-leptomeningeal-carcinomatosis-from-lung-adenocarcinoma-treated-with-erlotinib-and-gefitinib
#4
Jumpei Kashima, Yusuke Okuma, Maki Miwa, Yukio Hosomi
BACKGROUND: Leptomeningeal carcinomatosis is a relatively rare metastatic form of non-small cell lung cancer, which can impact prognosis. There is an increasing need for selecting suitable epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among those currently included in standard care for EGFR mutation-positive patients. We compared the efficacy of gefitinib and erlotinib in survival of patients with leptomeningeal carcinomatosis. PATIENTS AND METHODS: The medical records of 269 patients who received tyrosine kinase inhibitors at a single center were retrospectively reviewed...
January 6, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28030859/clinical-efficacy-of-afatinib-treatment-for-a-patient-with-leptomeningeal-carcinomatosis
#5
Yo Kawaguchi, Jun Hanaoka, Hideki Hayashi, Naoki Mizusaki, Hirotoshi Iihara, Yoshinori Itoh, Tadashi Sugiyama
Leptomeningeal metastases occur in 1% of patients with non-small-cell lung cancer. There have been several reports on the treatment of leptomeningeal metastases with afatinib. Our patient was a 41-year-old woman who had never smoked and was diagnosed with stage IV adenocarcinoma of the lung with an epidermal growth factor receptor (EGFR) mutation. She was treated with afatinib for the recurrence of leptomeningeal metastases. After the treatment with afatinib was initiated, the neurological symptoms dramatically regressed, and she achieved progression-free survival for 7 months...
December 29, 2016: Chemotherapy
https://www.readbyqxmd.com/read/27790117/rapid-response-to-high-dose-pulsatile-erlotinib-in-afatinib-refractory-leptomeningeal-carcinomatosis-from-adenocarcinoma-of-the-lung-a-case-report
#6
Frank S Fan
Leptomeningeal carcinomatosis occurred in an old female patient who was on a standard dose of afatinib for the treatment of her non-small cell lung cancer harboring an epidermal growth factor receptor gene mutation sensitive to tyrosine kinase inhibitors when extracranial lesions were still under control. Shifting to high-dose, pulsatile erlotinib dramatically saved her from the devastating condition in a very short period of time. Inadequate afatinib concentration in cerebrospinal fluid is reasonably suspected, and there is a call for clinical trials testing high-dose afatinib in leptomeningeal carcinomatosis...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27617103/leptomeningeal-carcinomatosis-in-non-small-cell-lung-cancer-initial-response-to-erlotinib-followed-by-relapse-despite-continuing-radiological-resolution-of-disease
#7
Alvin J X Lee, Rachel Benamore, Monika Hofer, Meenali Chitnis
A 60-year-old male was diagnosed with T3, N3, M1b epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma. Five months later he developed significant headaches, weakness and numbness of the left leg, and unsteadiness of gait. Magnetic resonance imaging (MRI) brain demonstrated subtle gyral enhancement indicative of early leptomeningeal infiltration. He was commenced on second-line erlotinib which improved his lower limb symptoms. Three months later he developed increased urinary frequency and redeveloped leg symptoms...
September 2016: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/27393516/intracranial-response-to-nivolumab-in-nsclc-patients-with-untreated-or-progressing-cns-metastases
#8
Elizabeth Dudnik, Shlomit Yust-Katz, Hovav Nechushtan, Daniel A Goldstein, Alona Zer, Dov Flex, Tali Siegal, Nir Peled
Central nervous system (CNS) metastases occur in 30% of patients with advanced non-small cell lung cancer (NSCLC). Localized treatments targeting CNS metastases result in delays in systemic therapy administration and are associated with neurocognitive impairment. Nivolumab is an immune check-point inhibitor that is approved as a second-line treatment of NSCLC. Data regarding the intracranial activity of nivolumab is lacking. We retrospectively reviewed the efficacy and safety of nivolumab in five patients with advanced NSCLC and new/progressing intracranial metastases...
August 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27306442/whole-brain-radiotherapy-in-management-of-non-small-cell-lung-carcinoma-associated-leptomeningeal-carcinomatosis-evaluation-of-prognostic-factors
#9
Yurday Ozdemir, Berna Akkus Yildirim, Erkan Topkan
To assess the efficacy of whole-brain radiotherapy (WBRT) and prognostic factors in leptomeningeal carcinomatosis (LMC) of non-small-cell lung cancer (NSCLC) patients. WBRT records of 51 LMC patients confined to brain were reviewed. Eligible patients had squamous-cell carcinoma (SCC) or adenocarcinoma, and Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-3. The WBRT was either 20 or 30 Gray. The primary and secondary objectives were to determine overall survival (OS) and prognostic factors for improved treatment response, respectively...
September 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/26845119/alectinib-dose-escalation-reinduces-central-nervous-system-responses-in-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-relapsing-on-standard-dose-alectinib
#10
Justin F Gainor, Andrew S Chi, Jennifer Logan, Ranliang Hu, Kevin S Oh, Priscilla K Brastianos, Helen A Shih, Alice T Shaw
The central nervous system (CNS) is an important and increasingly recognized site of treatment failure in anaplastic lymphoma kinase (ALK)-positive, non-small cell lung cancer (NSCLC) patients receiving ALK inhibitors. In this report, we describe two ALK-positive patients who experienced initial improvements in CNS metastases on standard dose alectinib (600 mg twice daily), but who subsequently experienced recurrences with symptomatic leptomeningeal metastases. Both patients were dose-escalated to alectinib 900 mg twice daily, resulting in repeat clinical and radiographic responses...
February 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/26496727/brain-metastasis-clinical-characteristics-pathological-findings-and-molecular-subtyping-for-therapeutic-implications
#11
REVIEW
Hidehiro Takei, Emilie Rouah, Yusuke Ishida
Metastases are the most common brain tumors especially in adults. Although they are generally considered a single disease entity which is universally fatal in patients with advanced cancer, brain metastases are remarkably heterogeneous both clinically and pathologically. As members of the multidisciplinary clinical team for the diagnosis and management of metastatic brain tumors, pathologists must be familiar not only with clinicopathologic features of brain metastases but also with any characteristic and clinically significant molecular findings...
January 2016: Brain Tumor Pathology
https://www.readbyqxmd.com/read/26334749/epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-for-non-small-cell-lung-cancer-patients-with-leptomeningeal-carcinomatosis
#12
Bin-Chi Liao, Jih-Hsiang Lee, Chia-Chi Lin, Ya-Fang Chen, Chin-Hao Chang, Chao-Chi Ho, Jin-Yuan Shih, Chong-Jen Yu, James Chih-Hsin Yang
BACKGROUND: Leptomeningeal carcinomatosis (LC) is a detrimental complication of patients with non-small-cell lung cancer (NSCLC). The effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on the clinical outcome of these patients, particularly those with EGFR mutations, has not been studied yet. METHODS: We searched the database for lung cancer patients diagnosed from 2003 to 2010 in one Asian medical center. NSCLC patients who also had LC diagnosed by either cytology or brain neuroimaging studies were identified...
December 2015: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/26141219/icotinib-might-be-effective-for-the-treatment-of-leptomeningeal-carcinomatosis-in-non-small-cell-lung-cancer-with-sensitive-egfr-mutations
#13
Lei Gong, Ming Xiong, Zhiyu Huang, Lulu Miao, Yun Fan
BACKGROUND: The incidence of leptomeningeal carcinomatosis (LMC) has increased in patients with metastatic non-small cell lung cancer (NSCLC). This study aimed to evaluate the effect of icotinib in the treatment of LMC. METHODS: Twenty-one NSCLC patients diagnosed with LMC and treated with icotinib were retrospectively reviewed. RESULTS: An exon 21 point mutation and an exon 19 deletion of EGFR were found in 10 and 11 patients, respectively...
September 2015: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/25921002/high-dose-erlotinib-for-refractory-leptomeningeal-metastases-after-failure-of-standard-dose-egfr-tkis
#14
Takahisa Kawamura, Akito Hata, Jumpei Takeshita, Shiro Fujita, Michio Hayashi, Keisuke Tomii, Nobuyuki Katakami
BACKGROUND: After initial response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), approximately one-third of patients develop central nervous system (CNS) metastases, including leptomeningeal metastases (LM). To achieve longer survival, control of CNS metastases is important, but therapeutic options are limited for LM after failure of standard-dose EGFR-TKIs. METHODS: We retrospectively evaluated the efficacy and safety of high-dose erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients with refractory LM after failure of standard-dose EGFR-TKIs...
June 2015: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/25568147/alectinib-induces-a-durable-15-months-complete-response-in-an-alk-positive-non-small-cell-lung-cancer-patient-who-progressed-on-crizotinib-with-diffuse-leptomeningeal-carcinomatosis
#15
Sai-Hong Ignatius Ou, Karen R Sommers, Michele C Azada, Edward B Garon
No abstract text is available yet for this article.
February 2015: Oncologist
https://www.readbyqxmd.com/read/24999085/afatinib-combined-with-cetuximab-for-lung-adenocarcinoma-with-leptomeningeal-carcinomatosis
#16
Chou-Han Lin, Ming-Tzer Lin, Yao-Wen Kuo, Chao-Chi Ho
We report a patient with non-small cell lung cancer (NSCLC) developed leptomeningeal carcinomatosis (LMC) after 4 years of multiple treatments. High-dose tyrosine kinase inhibitor (TKI) was given for LMC at first but was not effective. She then received dual therapy combining of afatinib and cetuximab. Brain magnetic resonance imaging (MRI) showed a partial response of disease and the patient experienced a clinical benefit. Our case suggests that dual targeting of epidermal growth factor receptor (EGFR) by a combination of afatinib and cetuximab can be a potential novel treatment option in treating LMC when high-dose TKI failed...
September 2014: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/24524822/prolonged-survival-of-patients-with-non-small-cell-lung-cancer-with-leptomeningeal-carcinomatosis-in-the-modern-treatment-era
#17
Jonathan W Riess, Seema Nagpal, Michael Iv, Michael Zeineh, Matthew A Gubens, Kavitha Ramchandran, Joel W Neal, Heather A Wakelee
INTRODUCTION: Leptomeningeal carcinomatosis (LM) is a severe complication of non-small-cell lung cancer (NSCLC) historically associated with poor prognosis. New chemotherapeutic and targeted treatments could potentially affect the natural history of LM. PATIENTS AND METHODS: Patients with a pathologic diagnosis of NSCLC with LM treated at Stanford between 2003 and 2011 were identified via institutional databases and medical records. LM was defined by cerebrospinal fluid (CSF) that was positive for malignant cells or by LM enhancement on magnetic resonance imaging with gadolinium contrast...
May 2014: Clinical Lung Cancer
https://www.readbyqxmd.com/read/24389440/the-central-nervous-system-as-a-sanctuary-site-in-alk-positive-non-small-cell-lung-cancer
#18
Justin F Gainor, Sai-Hong Ignatius Ou, Jennifer Logan, Lawrence F Borges, Alice T Shaw
Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct molecular subset of non-small-cell lung cancer that is highly responsive to treatment with the ALK inhibitor crizotinib. Recently, it has been recognized that the brain is a frequent site of relapse among ALK-positive patients treated with crizotinib. In this report, we expand on these observations and present a series of ALK-positive patients with two distinct forms of metastatic, central nervous system involvement: intramedullary spinal cord metastasis and leptomeningeal carcinomatosis...
December 2013: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/23804027/erlotinib-versus-gefitinib-for-control-of-leptomeningeal-carcinomatosis-in-non-small-cell-lung-cancer
#19
COMPARATIVE STUDY
Eunyoung Lee, Bhumsuk Keam, Dong-Wan Kim, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo
INTRODUCTION: Leptomeningeal carcinomatosis (LMC) from non-small-cell lung cancer (NSCLC) is a clinically important neurological complication in the era of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. METHODS: We retrospectively reviewed medical records of 25 EGFR TKI-treated NSCLC patients with LMC between 2004 and 2012 at Seoul National University Hospital...
August 2013: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/23584342/a-patient-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-with-development-of-leptomeningeal-carcinomatosis-while-on-targeted-treatment-with-crizotinib
#20
Jonathan W Riess, Seema Nagpal, Joel W Neal, Heather A Wakelee
Leptomeningeal carcinomatosis (LM) is an infrequent yet morbid and often fatal complication of non-small cell lung cancer (NSCLC). Management of LM is multimodal, often involving systemic chemotherapy, radiotherapy, and a variety of symptom management maneuvers to address elevated intracranial pressure, pain, and mood changes that can accompany the disease. It is increasingly recognized that tumors with actionable mutations in NSCLC, including epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations, respond well to systemic therapy with tyrosine kinase inhibitors yet often progress in the central nervous system...
April 1, 2013: Journal of the National Comprehensive Cancer Network: JNCCN
keyword
keyword
103304
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"